Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Titel:
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Auteur:
Riess, Jonathan W. Frankel, Paul Shackelford, David Dunphy, Mark Badawi, Ramsey D. Nardo, Lorenzo Cherry, Simon R. Lanza, Ian Reid, Joel Gonsalves, Wilson I. Kunos, Charles Gandara, David R. Lara, Primo N. Newman, Edward Paik, Paul K.